
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
5,001 - 15,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 1 epsHost
Recent guests
Recent episodes
Artificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings
Apr 10, 2026
21m 47s
Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA
Mar 26, 2026
33m 42s
Episode Rewind | From Submission to Success: Insider Tips for Getting Your Addiction Content Published
Feb 21, 2026
12m 56s
Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine
Feb 6, 2026
13m 01s
Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders
Jan 26, 2026
26m 29s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/10/26 | Artificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings✨ | Artificial IntelligenceStigma+3 | Dr. Nabila El-Bassel | American Society of Addiction MedicineArtificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings+1 | — | Artificial IntelligenceStigma+4 | — | 21m 47s | |
| 3/26/26 | ![]() Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA | In this episode, Dr. Jasmine Barnes and Dr. Margaret Lowenstein sit down to discuss their new article Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA featured in the January/February 2026 issue of the Journal of Addiction Medicine. Article Link: Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA | 33m 42s | ||||||
| 2/21/26 | ![]() Episode Rewind | From Submission to Success: Insider Tips for Getting Your Addiction Content Published | In today's Episode Rewind we're revisiting our interview with Dr. Marcela Smid, live at the 56th Annual ASAM Conference in Denver. Dr. Smid sits down to discuss article submissions and peer review, as well as demystifying the scientific publishing process for new authors. Learn more about this year's upcoming conference in San Diego, CA > https://bit.ly/3OTOx79 | 12m 56s | ||||||
| 2/6/26 | ![]() Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine | In this episode of Beyond The Abstract, Dr. Matthew Sloan sits down to discuss findings from his recent article Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine featured in the November/December issue of the Journal of Addiction Medicine. Join us as Dr. Sloan shares insights into his study investigating the feasibility of delivering symptom-triggered alcohol withdrawal management over telemedicine. Dr. Matthew Sloan is a clinician scientist at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. He specializes in the treatment of substance use disorders and their psychiatric comorbidities. He completed medical school and psychiatry residency at McGill University followed by a postdoctoral fellowship in human psychopharmacology at the National Institutes of Health and an addiction psychiatry fellowship at Yale University. Dr. Sloan's primary research interests are developing innovative new treatments for substance use disorders and exploring determinants of psychopharmacological response to drugs of misuse. He has obtained competitive research funding from the Canadian Institutes of Health Research, Health Canada, and the Centre for Addiction and Mental Health Discovery Fund and has received scientific prizes from the American Academy of Addiction Psychiatry and the National Institute on Alcohol Abuse and Alcoholism. Article Link: Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine | 13m 01s | ||||||
| 1/26/26 | ![]() Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders | In this episode, Dr. Nicolas Garel joins the podcast to discuss findings from his new article in the September/October issue of the Journal of Addiction Medicine titled Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study. Dr. Nicolas Garel is a psychiatrist and clinician-scientist at the Centre Hospitalier de l’Université de Montréal (CHUM). He is an assistant professor in the Department of Psychiatry at the Université de Montréal and adjunct professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. Dr. Garel completed his medical degree at the Université de Montréal, followed by his psychiatry residency and clinician-scientist fellowship at McGill University, and later pursued advanced training in research and addiction medicine at Stanford University. His research program focuses on innovative interventions for treatment-resistant mood disorders and substance use disorders. Article Link: Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study | 26m 29s | ||||||
| 1/8/26 | ![]() Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder | In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine. Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning. Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder | 15m 09s | ||||||
| 12/11/25 | ![]() Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes | In this episode, Dr. Bradley Stein joins the show to discuss findings from his new study titled Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes, featured in the September/October issue of the Journal of Addiction Medicine. Dr. Bradley Stein is a practicing physician and senior physician policy researcher at RAND. His research career has focused on improving access to, quality of, and outcomes from care of individuals with mental health and substance use disorders being treated in community settings. For two decades, Dr. Stein has studied the opioid crisis, serving as principal investigator for numerous federally and privately funded studies. He has published multiple peer-reviewed articles related to studies of opioid use disorder treatment, harm reduction, and the effects of state and federal policies, and he has provided Congressional testimony related to his research on multiple occasions. And his work has been covered by a range of media outlets including the Economist, Washington Post, and New York Times. Article Link: Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes Guest Editorial: Medicaid Unwinding May Have Substantially Disrupted Buprenorphine Treatment | 16m 10s | ||||||
| 11/28/25 | ![]() Non-medical Mephentermine Use: A Systematic Review of Literature | In this episode, Dr. Vinit Patel sits down to discuss his new article Non-medical Mephentermine Use: A Systematic Review of Literature, as well as what exactly mephentermine is, why and how it is currently being used in non-medical settings specifically in India and South Asia, and some of the contributing factors associated with geographic disparities in non-medical mephentermine use. Article Link: Non-medical Mephentermine Use: A Systematic Review of Literature | 46m 47s | ||||||
| 11/13/25 | ![]() Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service | Dr. Jennifer McNeely stops by the show to discuss her new article Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service. Article Link: Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service | 25m 44s | ||||||
| 9/18/25 | ![]() Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative | Dr. Pouya Azar stops by the show to talk about his recent article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review. Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar’s clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes. - Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative | 26m 02s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/28/25 | ![]() Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs | Host Dr. Shawn McNeil is joined by Dr. Robert Sherrick to discuss his new article Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs featured in the July/August issue of the Journal of Addiction Medicine. Robert Sherrick, MD, DFASAM, is chief science officer for Community Medical Services, a company that serves patients through over 70 Opioid Treatment Programs in 12 states. He also has experience working at an inpatient addiction treatment facility, Pathways Treatment Center, treating all forms of substance use disorders and dual diagnosis patients. Dr. Sherrick has been providing medication treatment for opioid use disorder since 2003, initially in an office setting using buprenorphine and subsequently with methadone in Opioid Treatment Programs. He established a state-wide buprenorphine treatment program for VA Montana with extensive use of telemedicine. He is board certified in internal medicine and addiction medicine through the American Board of Preventive Medicine. He is past president of the Northwest Chapter of the American Society of Addiction Medicine (ASAM). - Article: Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs | 17m 02s | ||||||
| 7/11/25 | ![]() Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem | Dr. Emily Pasman stops by the show to talk about her recent article Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem. She discusses the findings from her study as well as the potential limitations of using a solely abstinence-focused treatment and recovery model for addiction care. Emily Pasman is a licensed social worker and postdoctoral research fellow at the University of Michigan Center for the Study of Drugs, Alcohol, Smoking, and Health. Her research aims to improve health equity for people who use drugs by expanding harm reduction interventions; supporting affected family members; and addressing disparities in service access, uptake, and outcomes. Grounded in her practice background in peer-delivered services, she uses participatory methods to engage people with lived and living experience in all aspects of the research process. - Article Link: Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem | 19m 32s | ||||||
| 6/26/25 | ![]() Post Void Residuals: Medications for Opioid Use Disorder, Patient Outcomes, and How Not to Get Fooled by Urine Toxicology Results | Dr. Jarratt Pytell stops by the show to discuss his recent article featured in the Journal of Addiction Medicine titled Post Void Residuals: Medications for Opioid Use Disorder, Patient Outcomes, and How Not to Get Fooled by Urine Toxicology Results - Article Link: Void Residuals: Medications for Opioid Use Disorder, Patient Outcomes, and How Not to Get Fooled by Urine Toxicology Results | 24m 42s | ||||||
| 6/12/25 | ![]() The First 100 Days: The Trump Administration and Changes to Addiction Policy | In this episode, Regina LaBelle stops by to talk about her recent article featured in the Journal of Addiction Medicine titled, The First 100 Days: The Trump Administration and Changes to Addiction Policy. In this episode, Regina discusses structural, budgetary and personnel, and data collection changes that have occurred in the last 100 days and the potential impact on addiction policy. Regina LaBelle is the director of the Center on Addiction Policy at the O’Neill Institute for National and Global Health Law at Georgetown University Law Center. She is also a member of the faculty at Georgetown University’s Graduate School of Arts and Sciences, where she directs the Master of Science in Addiction Policy and Practice program, a program she founded in 2021. Regina has a history of public service, including in the Biden and Obama Administrations in the White House Office of National Drug Control Policy where she was appointed acting director in the first year of the Biden Administration. Under President Obama, Regina served as chief of staff at ONDCP where she managed the agency's response to the overdose epidemic and the implementation of the National Drug Control Strategy. She also serves on the National Advisory Council on Drug Abuse at the National Institutes of Health. - Article Link: The First 100 Days: The Trump Administration and Changes to Addiction Policy | 19m 58s | ||||||
| 5/29/25 | ![]() From Submission to Success: Insider Tips for Getting Your Addiction Content Published | Recorded live at the 56th Annual ASAM Conference in Denver, Dr. Marcela Smid sits down to discuss article submissions and peer review, as well as demystifying the scientific publishing process for new authors. | 12m 56s | ||||||
| 5/16/25 | ![]() Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder | In this episode, Dr. Charles Schauberger discusses the difficulties clinicians face when identifying and treating inhalant use in pregnant patients, and the findings from his recent article Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder. Dr. Charles Schauberger lives and practices in La Crosse, Wisconsin. He is board-certified in both Obstetrics and Addiction Medicine, and has developed a specialized pregnancy addiction clinic that champions a patient-centered approach to addiction care for pregnant women. While he is mostly retired from obstetrics, he continues to provide addiction care and continues his interest in performing research studies to advance our knowledge of treatment for substances in pregnancy. - Article Link: Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder | 11m 29s | ||||||
| 5/1/25 | ![]() Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis | In this episode, Dr. Mishka Terplan discusses initiation of MAUD for pregnant patients, and the findings from his recent article Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis. Dr. Mishka Terplan is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, public health, and advocacy interests lie along the intersections of reproductive and behavioral health. He is Medical Director at Friends Research Institute and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmline clinician. He is Co-Founder and Co-Director of Doing Right By Birth, a non-profit that seeks to flip the script from drug exposure to early childhood development. Dr. Terplan has spoken at local high schools and before the United States Congress and is internationally recognized as an expert in the care of pregnant and parenting people who use drugs. - Article Link: Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis | 25m 58s | ||||||
| 4/17/25 | ![]() Withdrawal Signs and Symptoms Among Patients Positive for Fentanyl With and Without Xylazine | In this episode, Dr. Ryan Alexander joins the show to discuss findings from his new study Withdrawal Signs and Symptoms Among Patients Positive for Fentanyl With and Without Xylazine. Dr. Ryan Alexander is an addiction medicine specialist and is currently the medical director for substance use services at McNabb Center in Knoxville, TN and is an assistant professor at the University of Tennessee Graduate School of Medicine. He completed medical school at the DeBusk College of Osteopathic Medicine in East Tennessee, his residency in preventive medicine and public health at Griffin Hospital/Yale School of Medicine, and a fellowship in addiction medicine at Yale University School of Medicine. In addition, he completed a Masters of Public Health at Yale School of Public Health. In addition to treating patients, Dr. Alexander conducts clinical research and has published multiple articles related to addiction medicine. He also regularly teaches medical students, residents, and other medical professionals about treating substance use disorders, reducing community stigma toward individuals with substance use disorders, and expanding access to medication treatments. - Article link: Withdrawal Signs and Symptoms Among Patients Positive for Fentanyl With and Without Xylazine | 13m 02s | ||||||
| 3/20/25 | ![]() Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers | In this episode, Dr. Ekaterina Pivovarova joins host Shawn McNeil to discuss the findings from her new article Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. Dr. Pivovarova is a licensed clinical psychologist and an associate professor in the Department of Family Medicine and Community Health at the University of Massachusetts Chan Medical School. - Article link: Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers | 28m 04s | ||||||
| 1/30/25 | ![]() Integration of a Community Opioid Treatment Program Into a Federally Qualified Health Center | In this episode, Dr. Christine Neeb sits down to discuss integrated treatment programs and how this model could potentially be adapted to other populations with SUD. Dr. Neeb is a Visiting Associate Professor and the Director of Integrated Primary Care and Addiction in the Division of General Internal Medicine at the University of Colorado Anschutz. She is board certified in Family Medicine and Addiction Medicine and focuses on novel strategies to expand access to treatment of substance use disorders, including methadone maintenance therapy, in underserved populations and in the primary care setting. - Integration of a Community Opioid Treatment Program Into a Federally Qualified Health Center | 14m 02s | ||||||
| 12/13/24 | ![]() Expert Panel Consensus of the Effectiveness and Implementation of Models to Support Posthospitalization Care Transitions for People With Substance Use Disorders | Podcast host Shawn McNiel, MD, is joined by Michael Incze, MD, MSEd to discuss his new article Expert Panel Consensus of the Effectiveness and Implementation of Models to Support Posthospitalization Care Transitions for People With Substance Use Disorders which aimed to establish a hierarchy of existing SUD care transition models in 2 categories-effectiveness and implementation-using an expert consensus approach. Dr. Michael Incze is a primary care physician in the Division of General Internal Medicine who is board certified in internal medicine and addiction medicine. His clinical interests include patient education, high value care, and caring for vulnerable populations including people experiencing homelessness and people with substance use disorders. He regularly volunteers at the Fourth Street Clinic, a federally qualified health center that specialized in providing care to people experiencing homelessness. He is a volunteer physician at the Rosebud Indian Health Service hospital in South Dakota. He also founded a clinic that focuses on providing primary care-based addiction treatment at Sugarhouse Health Center. | 22m 44s | ||||||
| 11/4/24 | ![]() The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients | In this episode of Beyond The Abstract, Dr. Joji Suzuki stops by the show to discuss his recent co-authored review on GLP-1 agonists and their potential role in addiction treatment. Dr. Suzuki is the founding Director of the Division of Addiction Psychiatry in the Department of Psychiatry, Brigham and Women’s Hospital (BWH), and an Associate Professor of Psychiatry at Harvard Medical School (HMS). He is board certified in both Addiction Psychiatry and Addiction Medicine, and has continued to maintain his clinical role as an inpatient addiction consultant at BWH. He has received NIH funding continuously since 2017, having completed a K23 Career Development Award to receive training in conducting clinical trials with an emphasis on research to improve the care of hospitalized patients. He is now a principal investigator on multiple NIH funded trials to evaluate novel pharmacologic and psychosocial treatments for substance use disorders. The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review Journal of Addiction Medicine 18(5):p 488-498, 9/10 2024 Sept-Oct 2024 | 23m 48s | ||||||
| 10/8/24 | ![]() Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality | Host Shawn McNeil, MD, is joined by Michelle Lofwall, MD, DFAPA, DFASAM, a professor in the Department of Behavioral Science and Psychiatry at the University of Kentucky and Medical Director of UK’s Robert Straus and First Bridge Clinics, which provide comprehensive OUD treatment within the UK Center on Drug and Alcohol Research. Dr. Lofwall and her co-authors examined the relationship between the dose in the early stages of treatment and the subsequent risk of death and found some surprising results. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality Journal of Addiction Medicine 18(3):p 319-326, 5/6 2024 May-June 2024 | 20m 04s | ||||||
| 6/6/24 | ![]() Hospital Initiatives to Transition SUD Patients from Acute Care to Community-based Services | Podcast host Shawn McNiel, MD, is joined by Noa Krawczyk, PhD, an assistant professor in the Department of Population Health at NYU Grossman School of Medicine, and an author of Initiatives to Support the Transition of Patients With Substance Use Disorders From Acute Care to Community-based Services Among a National Sample of Nonprofit Hospitals. Dr. Krawczyk discusses the gap in transition of acute care to community care services among most US hospitals, efforts to increase acute care interventions, and how clinicians providing SUD treatment can help hospitals identify and implement best practices to support continuity of care. Follow Dr. Krawczyk on Twitter @noakrawczyk Article, Authors, and Links: Initiatives to Support the Transition of Patients With Substance Use Disorders From Acute Care to Community-based Services Among a National Sample of Nonprofit Hospitals. Krawczyk, Noa PhD; Rivera, Bianca D. MPH; Chang, Ji E. PhD; Lindenfeld, Zoe MPH; Franz, Berkeley PhD Journal of Addiction Medicine 18(2):p 115-121, 3/4 2024 | 15m 41s | ||||||
| 4/24/24 | ![]() Xylazine Use Among People Who Inject Drugs, Philadelphia 2022 | Dr. Marissa Tan and her co-authors sought to help clinicians better identify individuals at risk and inform patients and clinicians about xylazine risk factors. | 13m 47s | ||||||
Showing 25 of 54
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.
